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Abstract
Objective This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine 
the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) 
and related disorders.
Methods We searched the following databases up to March 2018: PubMed, MEDLINE, EMBASE, Web of Science, and 
Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and 
evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran’s Q test and I-square 
(I2) statistic. Data were pooled using the random effect model and standardized mean difference (SMD) was considered as 
the summary effect size.
Results Six trials of 317 potential reports were identified to be suitable for our meta-analysis. The pooled results using ran-
dom effects model indicated that melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = − 1.80; 
95% CI − 3.27, − 0.32; P = 0.01; I2: 95.2) and interleukin 6 (IL-6) concentrations (SMD = − 2.02; 95% CI − 3.57, − 0.47; 
P = 0.01; I2: 91.2) among patients with MetS and related disorders; however, it did not affect tumor necrosis factor-α (TNF-
α) concentrations (SMD = − 1.87; 95% CI − 3.81, 0.07; P = 0.05; I2: 94.4).
Conclusions In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing 
CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders. Additional prospective studies are 
recommended using higher supplementation doses and longer intervention period.
Keyword Melatonin · Inflammatory markers · Meta-analysis
Introduction
Metabolic syndrome (MetS) is associated with increased 
systemic inflammation (Leisegang et al. 2016). This sta-
tus is seen more commonly in obese individuals com-
pared with lean people (Usta et al. 2018). Obesity and 
overweight cause the production and release of a variety 
of pro-inflammatory cytokines including interleukin-6 
(IL-6) and tumor necrosis factor-alpha (TNF-α), which 
in turn can induce the production of reactive oxygen spe-
cies (ROS) and free radicals (Fantuzzi 2005). It was previ-
ously reported that patients with MetS are susceptible to a 
two-fold increased risk of cardiovascular disease (CVD) 
over the subsequent 5–10 years (Alberti et al. 2009). In 
addition, increased levels of inflammatory cytokines play 
a key role in the progression of atherosclerotic events 
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(Ballantyne and Nambi 2005) and type 2 diabetes mel-
litus (T2DM) (Liu et al. 2016).
Complementary therapies including antioxidant supple-
mentation are recommended in individuals with MetS and 
related disorders to improve their nutritional status and 
boost their immune system (Tabrizi et al. 2017). Mecha-
nistic studies have documented the powerful antioxidant 
and anti-inflammatory actions of melatonin (Maldonado 
et al. 2016; Mauriz et al. 2013). Melatonin and its metabo-
lites directly scavenge free radicals, and reduce oxidative 
damage (Galano et al. 2013). Moreover, they stimulate 
gene expression related to antioxidant enzymes (Rodri-
guez et al. 2004). In addition, it has been suggested that 
melatonin decreases the production of pro-inflammatory 
markers by inhibiting the expression of TNF-α, IL-1β and 
IL-6 (Cuzzocrea and Reiter 2002; Radogna et al. 2010). 
In a study conducted by Mesri Alamdari et  al.(2015), 
melatonin supplementation at a dosage of 6 mg/day for 
40 days significantly reduced TNF-α and IL-6, but did not 
affect hs-CRP levels in obese women. In contrast, taking 
melatonin (10 mg/day) for 1 month by patients with severe 
and advanced atherosclerosis did not affect hs-CRP levels 
(Javanmard et al. 2016).
There are no systematic reviews or meta-analyses of 
randomized controlled trials (RCTs) assessing the effect 
of melatonin supplementation on inflammatory markers 
among individuals with MetS or related disorders. Thus, 
the present meta-analysis was conducted to summarize 
the available evidence regarding the effect of melatonin 
supplementation on inflammatory markers among patients 
with these conditions.
Materials and methods
Search strategy and selection studies
Two independent authors systematically searched the online 
databases, including Cochrane Library, EMBASE, PubMed, 
and Web of Science databases for relevant studies published 
before 30 March 2018. Searches were restricted to human 
clinical RCTs and those published in English. Two inde-
pendent authors performed the literature search to retrieve 
RCTs that have examined the association between melatonin 
supplementation and the inflammatory markers using the 
following MeSH and text keywords: patients [“Mets” OR 
“disorders related to MetS” OR “diabetes” OR “T1DM” OR 
“T2DM” OR “overweight” OR “obese” OR “chronic kidney 
disease (CKD)” OR “hypertension” OR “high blood pres-
sure” OR “dyslipidemia” OR “CVD”], intervention (“mela-
tonin” AND “supplementation” OR “intake”), and outcomes 
(“CRP “ OR “IL-6” OR “TNF-α”).
Inclusion and exclusion criteria
Two authors (MA and VO) investigated the titles/abstracts to 
identify related studies and to omit duplicates. Then the full 
texts of relevant studies were retrieved to ascertain whether 
these studies were suitable for our meta-analysis. RCTs were 
selected for analysis based on the following inclusion crite-
ria: the study was a human RCT (either parallel or cross-over 
design), and contained adequate data extracted from RCTs 
including the mean changes of CRP, IL-6, and TNF-α with 
standard deviations (SDs) and related 95% confidence inter-
vals (CIs) for the intervention and placebo groups. Other 
studies such as animal experiments, in vitro studies, case 
reports, observational studies, investigations without control, 
and studies that did not achieve the least quality assessment 
score were excluded from this meta-analysis.
Data extraction and quality assessment
Two independent authors (VO and MA) extracted the fol-
lowing data from selected studies: first authors’ name, year 
of publication, study location, age, study design, sample 
size, dose of intervention, duration of study, type of disease, 
the mean and standard deviation (SD) for CRP, IL-6, and 
TNF-α. When discrepancies occurred between the authors, 
it was resolved by discussion with a third author (ZA). The 
quality of the selected RCTs was assessed by two authors 
(MA and RT) independently using the Cochrane Collabora-
tion risk of bias tool based on the following criteria: “ran-
domization generation, allocation concealment, blinding of 
participants and outcome assessment, incomplete outcome 
data, and selective outcome reporting, and the other sources 
of bias”.
Data synthesis and statistical analysis
The authors determined the effects of melatonin sup-
plementation on the changes of the following outcomes: 
(1) CRP, (2) IL-6 and (3) TNF-α levels. The standard-
ised mean differences (SMDs) with 95% CI were used to 
pooled effect sizes using STATA software version 12.0 
(Stata Corp., College Station, TX) and RevMan V.5.3 
software (Cochrane Collaboration, Oxford, UK). Hetero-
geneity was assessed using Cochran’s Q test (with signifi-
cance P value lower than 0.1) and I-square test (I2 more 
than 50% showing significant heterogeneity). Since the 
indications influencing pooled SMD were different among 
included RCTs, we used random effects models to conduct 
meta-analyses. Sensitivity analyses were done to explore 
the impact of each included study on the reliability of the 
pooled mean difference using leave-one-out method. Also 
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subgroup analyses were conducted to assess the source 
of heterogeneity based on the potential moderator vari-
ables. Publication bias was examined using Egger’s regres-
sion tests. P values < 0.05 were considered as statistically 
significant.
Results
Figure 1 shows the flowchart of step by step study identifi-
cation and selection. Finally, six RCTs of 317 repots were 
selected to be included in our meta-analysis. All selected 
studies were randomized, double-blind, placebo-controlled 
trial design of which 316 persons were randomly assigned 
(159 subjects in intervention group and 157 in placebo 
group). Four trials assessed the effects of melatonin on 
CRP (Javanmard et al. 2016; Mesri Alamdari et al. 2015; 
Pakravan et al. 2017; Raygan et al. 2017), three trials on 
IL-6 (Celinski et al. 2014; Cichoz-Lach et al. 2010; Mesri 
Alamdari et al. 2015), and three on TNF-α levels (Celinski 
et al. 2014; Cichoz-Lach et al. 2010; Mesri Alamdari et al. 
2015). The sample size of RCTs included in this meta-anal-
ysis varied from 30 to 97 participants. Duration of interven-
tion ranged from 4 weeks to 14 months. The selected RCTs 
were published between 2010 and 2017. Dosage of mela-
tonin supplements ranged from 6 to 10 mg/day. The detailed 
characteristics of selected RCTs are summarized in Table 1.
The methodological quality assessment of RCTs based on 
Cochrane Collaboration risk of bias tool is shown in Fig. 2.
Main outcomes
Forest plots reporting the effect sizes of melatonin on 
inflammatory markers are indicated in Fig. 3. The pooled 
findings indicated that melatonin supplementation sig-
nificantly reduced CRP (SMD = − 1.80; 95% CI − 3.27, 
− 0.32; P = 0.01; I2: 95.2) and IL-6 concentrations levels 
(SMD = − 2.02; 95% CI − 3.57, − 0.47; P = 0.01; I2: 91.2) 
in patients with MetS and related disorders. Moreover, 
pooled findings from the random effects model did support 
Articles screened by title and 
abstract (n=119)
Full text articles assessed for 
eligibility (n=22)
Studies included in this study (n=6)
Article excluded (n=197) due to duplicate 
articles, not randomized controlled trials, 
review and not human 
Excluded non-relevant articles (n=97)
Articles excluded (n=16):
1. Not metabolic disease (n=9) 
2. Data presentation inappropriate for meta-
analysis (n=5)
3. Not placebo (n=2)
Articles identified through 
electronic database search (n=317)
Fig. 1  Literature search and review flowchart for selection of studies
Table 1  Characteristics of included studies
IL-6 interleukin-6, CRP C-reactive protein, TNF-α tumor necrosis factor-alpha, CHD coronary heart disease, MetS metabolic syndrome, T2DM 
type 2 diabetes mellitus, NAFLD non-alcoholic fatty liver disease
Authors (Ref) Publication year Sample size 
(control/inter-
vention)
Country/popula-
tion
Intervention 
(name and daily 
dose)
Duration Presented data Age (years) 
(control,
intervention)
Raygan et al. 
(2017)
2017 30/30 Iran/T2DM with 
CHD
10 mg melatonin 12 weeks CRP 65.3 ± 10.1, 
67.7 ± 11.4
Mesri Alamdari 
et al. (2015)
2014 22/22 Iran/obese 
women
6 mg melatonin 40 days CRP, IL-6, 
TNF-α
20–50 years
Pakravan et al. 
(2017)
2015 48/49 Iran/NAFLD 10 mg melatonin 3 months CRP 22–65 years
Celinski et al. 
(2014)
2014 23/23 Poland/NAFLD 10 mg melatonin 14 months IL-6, TNF-α 29.33 ± 9.58, 
36.16 ± 5.77
Cichoz-Lach 
et al. (2010)
2010 15/15 Poland/steato-
hepatitis
10 mg melatonin 4 weeks IL-6, TNF-α 22–58 years
Javanmard et al. 
(2016)
2016 19/20 Iran/CHD 10 mg melatonin 1 month CRP 58.63 ± 5.8, 
60.15 ± 6.3
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no significant impact of melatonin supplementation on 
TNF-α concentration (SMD = − 1.87; 95% CI − 3.81, 0.07; 
P = 0.059; I2: 94.4).
Pooled estimates of the SMDs based on the information at 
baseline and at the end of study in intervention and control 
groups are presented in Table 2.
Sensitivity analyses and subgroup analysis
The results of sensitivity analyses showed that the effect 
of melatonin on CRP, IL-6, and TNF-α levels was sensi-
tive to the studies conducted by Javanmard et al. (2016), 
Mesri Alamdari et al. (2015), and Cichoz-Lach et al. (2010), 
respectively. Excluding these studies from the analyses 
changed the pooled SMD effect of melatonin on CRP (SMD 
− 1.79; 95% CI − 3.26, 0.32), IL-6 (SMD − 1.30; 95% CI 
− 2.65, 0.03), and TNF-α (SMD − 2.77; 95% CI − 4.28, 
− 1.25). Table 3 reports the lower and higher pooled SMDs 
in the sensitivity analyses for inflammatory markers. The 
subgroup analyses were performed based on the following 
variables: geographic area (Iran vs. Poland), duration of 
study (≤ 8 weeks vs. > 8 weeks), and dosage of melatonin 
(6 vs. 10 mg melatonin). According to geographic area, 
there was a significant reduction in CRP concentrations 
using RCTs conducted in Iran (SMD − 1.80; 95% CI − 3.27, 
− 0.32). IL-6 concentrations reduced significantly in Iran 
studies as well (SMD − 3.54; 95% CI − 4.50, − 2.58), ver-
sus Poland studies (SMD − 1.31; 95% CI − 2.65, 0.04). For 
TNF-α, we observed similar findings including Iran stud-
ies (SMD − 2.03; 95% CI − 2.76, − 1.30), versus Poland 
studies (SMD − 1.80; 95% CI − 5.25, 1.65). The findings of 
subgroup analysis based on the duration of study revealed 
greater significant reduction in CRP concentrations in the 
strata of > 8 weeks intervention (SMD − 2.22; 95% CI, 
− 3.37, − 1.08) rather than the strata of ≤ 8 weeks (SMD 
− 1.38; 95% CI − 4.57, 1.38). Similarly, the melatonin sup-
plementation significantly decreased IL-6 levels in the sub-
group with duration > 8 weeks (SMD − 2.22; 95% CI − 3.37, 
− 1.08) compared to ≤ 8 weeks subgroup (SMD − 2.22; 95% 
CI − 3.37, − 1.08) and for TNF-α levels, we observed simi-
lar findings based on the duration of intervention > 8 weeks 
(SMD − 1.99; 95% CI − 2.70, − 1.28) versus ≤ 8 weeks 
(SMD − 2.06; 95% CI − 4.92, 0.80). The findings of sub-
group analysis based on the quality assessment score indi-
cated that melatonin supplementation significantly decreased 
CRP levels in RCTs with high risk of bias (SMD − 2.22; 
95% CI − 3.37, − 1.08) compared with RCTs having unclear 
risk (SMD − 1.38; 95% CI − 4.57, 1.38). The detailed find-
ings of subgroups analyses are summarized in Table 4.
Publication bias
Egger’s regression test was applied to determine the prob-
ability of publication bias among RCTs included in the 
meta-analysis. This test showed no significant evidence of 
publication bias for meta-analyses assessing the effect of 
melatonin on CRP (B = − 6.69, P = 0.69), IL-6 (B = − 16.93, 
P = 0.43) and TNF-α levels (B = − 24.07, P = 0.38).
Discussion
To our best knowledge, this is the first meta-analysis of RCTs 
that evaluated the effects of melatonin supplementation on 
inflammatory markers among individuals with metabolic 
Fig. 2  The methodological quality of included studies (risk of bias)
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diseases. In the present meta-analysis, we clarified that mela-
tonin supplementation significantly reduced CRP and IL-6, 
but did not affect TNF-α levels in patients with MetS or 
related disorders. Generally, inflammatory markers increase 
in not only metabolic conditions, but also in multiple non-
metabolic disorders including rheumatoid arthritis (Zhang 
et al. 2014) and cystic fibrosis (Bruscia and Bonfield 2016). 
Moreover, metabolic abnormalities with the inflammation 
as one of their main pathophysiological causes are part of 
different chronic conditions including obesity, T2DM, CVD, 
stroke, fatty liver, and other metabolic diseases. Therefore, 
due to similar metabolic status, different metabolic disorders 
were included in the current meta-analysis.
The published clinical literature about the effects of mela-
tonin supplementation on inflammatory markers is scarce. 
In a study conducted by Pakravan et al. (2017), melatonin 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 95.2%, p = 0.000)
First_author
Raygan F
Mesri Alamdari N
Javanmard S
Pakravan H
Year
2017
2014
2016
2015
Country
Iran
Iran
Iran
Iran
Total_SS
60
44
39
97
-1.80 (-3.27, -0.32)
SMD (95% CI)
-1.64 (-2.22, -1.05)
0.22 (-0.37, 0.82)
-3.03 (-3.96, -2.10)
-2.81 (-3.37, -2.24)
100.00
Weight
25.35
25.33
23.89
25.43
0-3.96 3.96
NOTE: Weights are from random effects analysis
Overall  (I-squared = 91.2%, p = 0.000)
Celinski K
First_author
Cichoz-Lach H
Mesri Alamdari N
2014
Year
2010
2014
Poland
Country
Poland
Iran
46
Total_SS
30
44
-2.02 (-3.57, -0.47)
-1.99 (-2.70, -1.28)
SMD (95% CI)
-0.62 (-1.35, 0.11)
-3.54 (-4.50, -2.58)
100.00
34.01
Weight
33.86
32.12
0-4.5 4.5
A
B
Fig. 3  Meta-analysis glycemic control standardized mean differences estimates for (a) high-sensitivity C-reactive protein, (b) for interleukin-6, 
and (c) for tumor necrosis factor-alpha in melatonin supplements and placebo groups (CI = 95%)
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 94.4%, p = 0.000)
Cichoz-Lach H
Mesri Alamdari N
First_author
Celinski K
2010
2014
Year
2014
Poland
Iran
Country
Poland
30
44
Total_SS
46
-1.87 (-3.81, 0.07)
-0.06 (-0.77, 0.66)
-2.03 (-2.76, -1.30)
SMD (95% CI)
-3.58 (-4.52, -2.63)
100.00
33.73
33.65
Weight
32.62
0-4.52 4.52
Fig. 3  (continued)
Table 2  The effects of melatonin supplementation on inflammatory markers based on subgroup analysis
IL-6 interleukin-6, CRP C-reactive protein, TNF-α tumor necrosis factor-alpha
Variables Number 
of study
Standardized 
mean difference
CI 95% P value Heterogeneity
I2 (%) Q P value 
heteroge-
neity
CRP Intervention group (after vs. before) 4 − 1.13 − 1.70, − 0.55 < 0.001 75.5 12.24 0.007
Placebo group (after vs. before) 4 − 0.47 − 1.48, 0.53 0.356 92.2 38.62 < 0.001
Change intervention group vs. placebo group 4 − 1.80 − 3.27, − 0.32 0.017 95.2 62.91 < 0.001
IL-6 Intervention group (after vs. before) 3 − 1.03 − 1.73, − 0.32 0.004 69.6 6.57 0.037
Placebo group (after vs. before) 3 − 0.29 − 0.65, 0.07 0.114 0.0 1.38 0.502
Change intervention group vs. placebo group 3 − 2.02 − 3.57, -0.47 0.010 91.2 22.83 < 0.001
TNF-α Intervention group (after vs. before) 3 − 2.40 − 4.44, − 0.37 0.020 94.1 33.91 < 0.001
Placebo group (after vs. before) 3 − 0.96 − 1.73, − 0.19 0.015 74.8 7.94 0.019
Change intervention group vs. placebo group 3 − 1.87 − 3.81, 0.07 0.059 94.4 35.99 < 0.001
Table 3  The assessment of association between melatonin supplementation on inflammatory markers based on subgroup analysis
IL-6 interleukin-6, CRP C-reactive protein, TNF-α tumor necrosis factor-alpha
Variables Pre-sensitivity analysis Upper and lower 
of effect size
Post-sensitivity analysis
No. of studies 
included
Pooled SMD
(random effect)
95% CI Pooled SMD
(random effect)
95% CI Excluded
studies
CRP 4 − 1.80 − 3.27, − 0.32 Upper − 1.79 − 3.26, 0.32 Javanmard
Lower − 2.45 − 3.33, − 1.57 Mesri Alamdari
IL-6 3 − 2.02 − 3.57, − 0.47 Upper − 1.30 − 2.65, 0.03 Mesri Alamdari
Lower − 2.73 − 4.24, − 1.21 Cichoz-Lach
TNF-α 3 − 1.87 − 3.81, 0.77 Upper − 1.04 − 2.97, 0.89 Celinski
Lower − 2.77 − 4.28, − 1.25 Cichoz-Lach
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supplementation for 12 weeks to patients with non-alcoholic 
fatty liver disease significantly reduced hs-CRP concentra-
tions. In addition, Mesri Alamdari et al. (2015) demonstrated 
that melatonin supplementation (6 mg/day) for 40 days 
lowered TNF-α and IL-6 levels in obese women, but did 
not affect hs-CRP levels. Taking 10 mg/day melatonin for 
12 weeks by diabetic patients with CVD was associated 
with a significant reduction in hs-CRP levels (Raygan et al. 
2017). Conversely, melatonin administration (10 mg/day) 
for 1 month to the patients with severe and advanced athero-
sclerosis did not influence hs-CRP levels (Javanmard et al. 
2016). Different study designs, different baseline values of 
dependent variables, different doses of melatonin used along 
with characteristics of study participants might explain the 
discrepancies among included studies. Elevated levels of 
CRP are associated with insulin resistance, the incidence 
of T2DM and the increased risk of CVD (Odegaard et al. 
2016). A review on micro-inflammation has suggested a 
possible mechanistic link between a pro-inflammatory diet 
and MetS (Tang et al. 2015). Moreover, a meta-analysis of 
16 studies reported a relation between hs-CRP levels and 
the incidence of diabetes (Lee et al. 2009) although a nested 
case–control study in the European Prospective Investigation 
of Cancer (EPIC)-Norfolk cohort demonstrated that this cor-
relation might be confounded by central adiposity (Lee et al. 
2009). With respect to CVD, higher circulating levels of 
hs-CRP were independently correlated with carotid intima-
media thickness (Willeit et al. 2016). In a meta-analysis 
conducted by Kaptoge et al. (2010), there was a significant 
association between hs-CRP levels and the risk of coronary 
heart disease, stroke and both vascular and non-vascular 
mortality. Melatonin may reduce inflammation through 
downregulation of the nuclear factor kappa B (Veneroso 
et al. 2009), thereby suppressing the upregulation of a vari-
ety of pro-inflammatory markers (Mauriz et al. 2013) as well 
as reducing tissue/organ damage (Chen et al. 2014; Galano 
et al. 2013). In addition, melatonin may decrease inflamma-
tory markers through scavenging toxic oxygen derivatives 
in the inflamed tissues (Radogna et al. 2010).
This meta-analysis has some limitations. The number of 
eligible RCTs included was low, and most of them included 
a modest number of participants. Various doses of melatonin 
were administered for intervention in the included studies. 
We were unable to evaluate the dose–response relation 
Table 4  The assessment of association between melatonin supplementation on inflammatory markers based on subgroup analysis
IL-6 interleukin-6, CRP C-reactive protein, TNF-α tumor necrosis factor-alpha
Variables Number of 
SMD included
Subgroups Pooled OR (ran-
dom effect)
95% CI I2 (%) Overall
I2 (%)
CRP Geographic area 4 Iran − 1.80 − 3.27, − 0.32 95.2 95.2
– Poland – – –
Duration of study (week) 2 > 8 weeks − 2.22 − 3.37, − 1.08 87.4
2 ≤ 8 weeks − 1.38 − 4.57, 1.38 97.0
Dosage of melatonin (mg/day) 3 10 mg melatonin − 2.45 − 3.34, − 1.57 80.4
1 6 mg melatonin 0.22 − 0.37, 0.82 –
Quality assessment score 2 High risk − 2.22 − 3.37, − 1.08 87.4
2 Unclear risk − 1.38 − 4.57, 1.38 97.0
IL-6 Geographic area 1 Iran − 3.54 − 4.50, − 2.58 – 91.2
2 Poland − 1.31 − 2.65, 0.04 85.5
Duration of study (week) 1 >8 weeks − 1.99 − 2.70, − 1.28 –
2 ≤8 weeks − 2.06 − 4.92, 0.80 95.5
Dosage of melatonin (mg/day) 2 10 mg melatonin − 1.31 − 2.65, 0.04 85.5
1 6 mg melatonin − 3.54 − 4.50, − 2.58 –
Quality assessment score – High risk – – –
3 Unclear risk − 2.02 − 3.57, − 0.47 91.2
TNF-α Geographic area 1 Iran − 2.03 − 2.76, − 1.30 – 94.4
2 Poland − 1.80 − 5.25, 1.65 97.0
Duration of study (week) 1 >8 weeks − 3.58 − 4.52, − 2.63 –
3 ≤8 weeks − 1.04 − 2.97, 0.89 93.0
Dosage of melatonin (mg/day) 2 10 mg melatonin − 1.80 − 5.25, 1.65 97.0
1 6 mg melatonin − 2.03 − 2.76, − 1.30 –
Quality assessment score – High risk – – –
3 Unclear risk − 1.87 − 3.81, 0.07 94.4
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between supplementation and inflammatory markers due 
to the low number of studies included. In addition, RCTs 
included in our meta-analysis were represented with dif-
ferent chronic conditions and study durations, which might 
potentially skew the data. However, all selected patients in 
our meta-analysis had some kind of metabolic disorders and 
the main outcome of interest was inflammation. Previous 
studies have documented the increased levels of inflamma-
tory markers in patients with MetS, diabetes (Ben-Shmuel 
et al. 2016), being overweight, CKD (Zoccali 2009), hyper-
tension and CVD (Mozos et al. 2017). Due to mentioned 
limitations of this study, in discussion and conclusion, 
though, we interpreted our results cautiously. Most of the 
studies included in our analyses had small sample sizes and 
low duration of intervention. Trial with small sample sizes 
might be less robust, and more susceptible to report larger 
effect sizes (Nuesch et al. 2010).
Conclusions
In summary, the current meta-analysis showed a promis-
ing action of melatonin administration for reducing CRP 
and IL-6 levels in patients with MetS and related disorders. 
Additional prospective studies regarding the effect of mela-
tonin supplementation on inflammatory markers in patients 
with MetS and related disorders seem necessary.
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